Literature DB >> 23328447

Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases.

Keiji Kuba1, Yumiko Imai, Josef M Penninger.   

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a negative regulator of the renin-angiotensin system, and functions as the key SARS coronavirus receptor and stabilizer of neutral amino acid transporters. ACE2 catalyzes the conversion of angiotensin II to angiotensin 1-7, thereby counterbalancing ACE activity. Accumulating evidence indicates that the enzymatic activity of ACE2 has a protective role in cardiovascular diseases. Loss of ACE2 can be detrimental, as it leads to functional deterioration of the heart and progression of cardiac, renal, and vascular pathologies. Recombinant soluble human ACE2 protein has been demonstrated to exhibit beneficial effects in various animal models, including cardiovascular diseases. ACE2 is a multifunctional enzyme and thus potentially acts on other vasoactive peptides, such as Apelin, a vital regulator of blood pressure and myocardium contractility. In addition, ACE2 is structurally a chimeric protein that has emerged from the duplication of 2 genes: homology with ACE at the carboxypeptidase domain and homology with Collectrin in the transmembrane C-terminal domain. ACE2 has been implicated in the pathology of Hartnup's disease, a disorder of amino acid homeostasis, and, via its function in amino acid transport, it has been recently revealed that ACE2 controls intestinal inflammation and diarrhea, thus regulating the gut microbiome. This review summarizes and discusses the structure and multiple functions of ACE2 and the relevance of this key enzyme in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328447     DOI: 10.1253/circj.cj-12-1544

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  58 in total

Review 1.  Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.

Authors:  Rossella Talotta; Erle S Roberston
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

2.  Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro.

Authors:  Philipp K Haber; Minghao Ye; Jan Wysocki; Christoph Maier; Syed K Haque; Daniel Batlle
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

Review 3.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

4.  Hypertensive urgencies and emergencies: Misconceptions and pitfalls.

Authors:  Fabio Angeli; Gianpaolo Reboldi; Paolo Verdecchia
Journal:  Eur J Intern Med       Date:  2019-11-06       Impact factor: 4.487

5.  The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke.

Authors:  Yan-Hui Wu; Jia-Ying Li; Chi Wang; Li-Mei Zhang; Hong Qiao
Journal:  J Clin Lab Anal       Date:  2016-08-08       Impact factor: 2.352

Review 6.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): A scoping review.

Authors:  Sabitha Vadakedath; Venkataramana Kandi; Ranjan K Mohapatra; Venkata B K Pinnelli; Richa R Yegurla; Praveen R Shahapur; Vikram Godishala; Senthilkumar Natesan; Kranti S Vora; Khan Sharun; Ruchi Tiwari; Muhammad Bilal; Kuldeep Dhama
Journal:  J Med Virol       Date:  2021-05-19       Impact factor: 20.693

Review 8.  Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19.

Authors:  Luise Hassler; Fabiola Reyes; Matthew A Sparks; Paul Welling; Daniel Batlle
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-14       Impact factor: 8.237

Review 9.  Cell entry by SARS-CoV-2.

Authors:  Ruchao Peng; Lian-Ao Wu; Qingling Wang; Jianxun Qi; George Fu Gao
Journal:  Trends Biochem Sci       Date:  2021-06-07       Impact factor: 13.807

Review 10.  SARS-CoV-2: is there neuroinvasion?

Authors:  Conor McQuaid; Molly Brady; Rashid Deane
Journal:  Fluids Barriers CNS       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.